NewsRoom Articles - Page 692 of 1389

TuesdayOct 29, 2019 12:45 pm

WidePoint Corp. (NYSE: WYY) Starts Presentation at Dawson James Small Cap Growth Conference

WidePoint (NYSE: WYY) delivers secure, cloud-based, enterprise-wide information technology-based solutions that can enable commercial enterprises and government agencies to deploy fully compliant IT services in accordance with government-mandated regulations and advanced system requirements. The company offers unique solutions in certificate-based security solutions, wireless telecommunication expense management systems, and associated consulting services. WidePoint's diverse portfolio of clients includes global and international organizations across a multitude of industries. For more information, visit the company's website at www.widepoint.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all…

TuesdayOct 29, 2019 12:17 pm

VPR Brands LP (VPRB) Reaps Benefit of Growing Social Media Buzz over CBD, Focuses on CBD Product Lines

CBD is a key piece of VPR Brands’ product development and marketing, with its GOLDLINE CBD products serving as a significant new entrant into the space The company recently exhibited its new GOLDLINE product offerings, including CBD oil, CBD-oil cartridges, gummies and CBD-oil tinctures, at NACS Expo VPRB grew sales to $1.58 million in Q2 2019, marking a 31 percent jump from the comparable period of the prior year VPR Brands LP (OTCQB: VPRB), a multi-vertical tiered technology holding company in the cannabis space, is expanding and focusing on CBD products as the term ‘CBD’ is itself becoming more significant…

TuesdayOct 29, 2019 11:45 am

VolitionRx Ltd. (NYSE: VNRX) Starts Presentation at Dawson James Small Cap Growth Conference

VolitionRx (NYSE: VNRX) is a multi-national life sciences company focused on developing simple and easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Volition intends to expand the application of its technology beyond cancer by exploring other disease applications. For more information, visit the…

TuesdayOct 29, 2019 11:27 am

OriginClear Inc. (OCLND) Reports Pilot-Project Win as Proprietary Technology Produces Clear Water from Pig Manure

The success of the pilot project opens up exciting possibilities for OriginClear in animal-wastewater treatment space OriginClear has partners in Europe’s top two hog-production markets The need for on-premises water treatment is growing as central facilities fail and treatment costs rise OriginClear Inc. (OTC: OCLND) CEO Riggs Eckelberry and President Bill Charneski provided an impressive update during a recent CEO briefing, discussing the success of a pilot project the company is spearheading in Spain (http://nnw.fm/5eaNu). The project combines OriginClear’s proprietary Electro Water Separation™ technology with its exclusive Advanced Oxidation process (AOx) that recycles manure water into clean, usable water (http://nnw.fm/MD0sl).…

TuesdayOct 29, 2019 11:20 am

Artelo Biosciences Inc. (NASDAQ: ARTL) Starts Presentation at Dawson James Small Cap Growth Conference

Artelo Biosciences (NASDAQ: ARTL) is applying exacting biopharma discipline toward developing and commercializing a diverse portfolio of novel therapeutic candidates targeting the endocannabinoid system. By leveraging past research and leading-edge, world-class science, Artelo is rapidly advancing a portfolio of endocannabinoid system modulating therapeutics. The company's broadly applicable product candidates have the potential to dramatically improve patient care in multiple major markets. Artelo expects to deliver on the promise of new therapeutic medicines to treat a wide range of diseases and conditions, creating value for patients, the medical community and investors. For more information, visit the company's website at www.artelobio.com. About NetworkNewsWire…

TuesdayOct 29, 2019 11:20 am

Atossa Genetics Inc. (NASDAQ: ATOS) Starts Presentation at Dawson James Small Cap Growth Conference

Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. Atossa is developing "endoxifen" to mitigate breast cancer risk by reducing the density of breast tissue; to reduce the cancer cell activity before surgery; and to reduce the risk of recurrent or new breast cancer after the initial treatment. The company is also developing a new way to deliver therapies, such as "CAR-T" cells, through microcatheters directly to the site of breast cancer. The company believes its innovative therapies and delivery methods can transform breast cancer treatment…

TuesdayOct 29, 2019 10:55 am

Fortress Biotech Inc. (NASDAQ: FBIO) Starts Presentation at Dawson James Small Cap Growth Conference

Fortress Biotech (NASDAQ: FBIO) is an innovative biopharmaceutical company identifying, in-licensing and developing high-potential clinical-stage assets. The company has over 25 programs in clinical development at Fortress, at its majority-owned and majority-controlled subsidiaries, and at entities it founded and holds significant minority ownership positions. The product candidates span six large-market therapeutic areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders. The company advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. Fortress has established partnerships with some of the world's leading academic research institutions and…

TuesdayOct 29, 2019 10:55 am

CEL-SCI Corp. (NYSE: CVM) Starts Presentation at Dawson James Small Cap Growth Conference

CEL-SCI (NYSE: CVM) is at the forefront in the research and development of products for the treatment of cancer, autoimmune and infectious diseases. CEL-SCI believes that boosting a patient's immune system while still intact should provide the greatest possible impact on survival. The company's core capabilities include drug discovery, research, development and manufacturing of complex biological substances. CEL-SCI's phase 3 study is the largest phase 3 study in the world for the treatment of head and neck cancer, and after 8.5 years is very close to completion. Multikine, CEL-SCI's lead investigational therapy, is a potential therapeutic agent directed at enabling…

TuesdayOct 29, 2019 10:30 am

IMAC Holdings Inc. (NASDAQ: IMAC) Starts Presentation at Dawson James Small Cap Growth Conference

IMAC Holdings (NASDAQ: IMAC) combines life science advancements with traditional medical care for movement-restricting diseases and conditions. The company owns or manages outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. IMAC Regeneration Centers provide medical services for movement-restricting conditions. It has partnered with several active and former professional athletes, including brand ambassadors Ozzie Smith, David Price, Tony Delk and Mike Ditka. IMAC's outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries without surgery or opioids. For more information, visit the company's website at www.imacregeneration.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content…

TuesdayOct 29, 2019 10:30 am

Dyadic International Inc. (DYAI) Starts Presentation at Dawson James Small Cap Growth Conference

Dyadic International (NASDAQ: DYAI) is a global biotechnology company developing a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large-scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is leveraging its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and…

Financial news and publishing for public and private companies

Contact us: 512.354.7000